

Stephanie K Dougan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1277245/publications.pdf>

Version: 2024-02-01

34
papers

3,472
citations

257450

24
h-index

377865

34
g-index

34
all docs

34
docs citations

34
times ranked

6417
citing authors

#	ARTICLE	IF	CITATIONS
1	Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. <i>Nature Biotechnology</i> , 2015, 33, 538-542.	17.5	945
2	Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. <i>Gastroenterology</i> , 2019, 156, 2056-2072.	1.3	300
3	GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. <i>Immunity</i> , 2019, 50, 796-811.	14.3	274
4	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020, 182, 655-671.e22.	28.9	259
5	Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. <i>Journal of Experimental Medicine</i> , 2005, 202, 529-539.	8.5	142
6	Anti-CTLA-4 therapy requires an Fc domain for efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3912-3917.	7.1	121
7	EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 444-456.	13.2	118
8	Understanding and treating the inflammatory adverse events of cancer immunotherapy. <i>Cell</i> , 2021, 184, 1575-1588.	28.9	111
9	Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. <i>Gut</i> , 2015, 64, 1889-1897.	12.1	106
10	Localized CD47 blockade enhances immunotherapy for murine melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10184-10189.	7.1	103
11	Eosinophils in Health and Disease: A State-of-the-Art Review. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2694-2707.	3.0	103
12	Cancer Immunotherapy: Beyond Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2019, 3, 55-75.	4.5	102
13	PD-L1 is an activation-independent marker of brown adipocytes. <i>Nature Communications</i> , 2017, 8, 647.	12.8	97
14	Translational advances in pancreatic ductal adenocarcinoma therapy. <i>Nature Cancer</i> , 2022, 3, 272-286.	13.2	90
15	Longitudinal multiparameter assay of lymphocyte interactions from onset by microfluidic cell pairing and culture. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3599-608.	7.1	78
16	Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2030.	4.8	77
17	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. <i>Cancer Immunology Research</i> , 2018, 6, 389-401.	3.4	68
18	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. <i>Cancer Discovery</i> , 2021, 11, 2564-2581.	9.4	58

#	ARTICLE	IF	CITATIONS
19	Regulation of innate and adaptive antitumor immunity by IAP antagonists. <i>Immunotherapy</i> , 2018, 10, 787-796.	2.0	51
20	Generation of Ca ²⁺ -independent sortase A mutants with enhanced activity for protein and cell surface labeling. <i>PLoS ONE</i> , 2017, 12, e0189068.	2.5	34
21	Monoclonal Invariant NKT (iNKT) Cell Mice Reveal a Role for Both Tissue of Origin and the TCR in Development of iNKT Functional Subsets. <i>Journal of Immunology</i> , 2017, 199, 159-171.	0.8	30
22	Programmable bacteria as cancer therapy. <i>Nature Medicine</i> , 2019, 25, 1030-1031.	30.7	29
23	IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells. <i>Cancer Immunology Research</i> , 2018, 6, 25-35.	3.4	27
24	CD1d-Restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10449-10454.	7.1	26
25	clAP1/2 antagonism eliminates MHC class II ⁺ negative tumors through T cell ⁺ dependent reprogramming of mononuclear phagocytes. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	25
26	Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity. <i>Journal of Experimental Medicine</i> , 2018, 215, 2617-2635.	8.5	20
27	Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8 ⁺ T Cell ⁺ Effector Responses. <i>Cancer Immunology Research</i> , 2018, 6, 1524-1536.	3.4	17
28	Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer. <i>Open Biology</i> , 2021, 11, 210245.	3.6	15
29	Type 2 immunity is maintained during cancer-associated adipose tissue wasting. <i>Immunotherapy Advances</i> , 2021, 1, ltab011.	3.0	13
30	Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. <i>Open Biology</i> , 2020, 10, 190235.	3.6	11
31	Dangerous dynamic duo: Lactic acid and PD-1 blockade. <i>Cancer Cell</i> , 2022, 40, 127-130.	16.8	10
32	Tissue eosinophils express the IL ³³ receptor ST2 and type 2 cytokines in patients with eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 656-660.	5.7	8
33	Transnuclear mice reveal Peyer's patch iNKT cells that regulate B cell class switching to IgG1. <i>EMBO Journal</i> , 2019, 38, e101260.	7.8	3
34	SMAC mimetics throw a molecular switch to control T _H 17 responses. <i>Science Signaling</i> , 2019, 12, .	3.6	1